The partnership represents one of the most innovative and comprehensive collaborations in the oncology drug development arena. As part of the agreement, the Cancer Therapy and Research Center (CTRC) Research Foundation will conduct preclinical and clinical research.

"Our unique alliance with Lilly, PRN and CTRC Research -- integrating contract research, consultative trial design service and patient access -- enables us to more effectively deal with clinical trial design issues, patient accrual and data management. This marks a major advance toward significantly reducing cancer drug development time while maintaining the highest standards of data quality," said Richard Love, President and CEO, ILEX Oncology, Inc. "It is particularly gratifying for ILEX to participate in this partnership, as it demonstrates our ability to execute large-scale development programs and truly provide solutions for accelerated drug development," Mr. Love added.

Bob Whren, Executive Vice President, Subsidiary Operations, PRN, stated, "We are excited to offer trial design expertise and serve as a clinical research site for the development of these important compounds. This collaboration reflects PRN's commitment to provide patients access to the latest therapeutic advances, and the convenience of participating in clinical trials close to home." Annually, physicians affiliated with PRN treat more than 50,000 new cancer patients.

Under the agreement, ILEX Oncology will serve as the contract research organization (CRO) for Lilly, managing the clinical development of both compounds -- from phase I through phase III. PRN and CTRC Research will participate in clinical trial design and serve as research trial sites. Dr. Daniel D. Von Hoff, who provides leadership to ILEX, PRN and CTRC Research, brings extensive expertise in protocol design and product development.

"We have streamlined the development process," explained Kathy Heck, Director of Clinical Research Services at ILEX. "Working in concert with Lilly's scientists, we were able to develop protocols within weeks. We are enrolling patients four months after our initial protocol development meeting."

Commenting on the agreement, Homer L. Pearce, Ph.D., Vice President, Cancer Research and Clinical Investigation at Lilly, stated, "We are delighted to join ILEX, PRN, and CTRC in a collaboration to expedite the clinical development of two of the investigational drugs in Lilly's oncology pipeline. This collaboration allows all parties to exploit their great strengths in drug development in order to bring new therapies to the cancer patient."

ILEX Oncology, Inc., is a drug development company focused exclusively on developing and obtaining marketing approval of drugs for the treatment and prevention of cancer. ILEX Oncology provides pharmaceutical and biotechnology companies with compounds for their pipeline as well as drug development and manufacturing services on a contract basis. ILEX's close association with cancer research and treatment institutions allows access to both the opinion leaders and patients necessary for the development of oncology drugs.

PRN is the largest oncology practice management organization in the United States, and is based in Dallas, Texas. PRN provides management facilities, administration, technical support, ancillary services and research services necessary to establish and maintain a fully-integrated oncology network. The company manages in excess of 300 physicians in 108 practice locationsincluding 17 cancer centers.

Just type your keywords in the space provided below, then click on the Search button.

---

---

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.

All contents Copyright (c) 1995 P\S\L Consulting Group Inc. All rights reserved.